Prostatype Genomics AB (publ) (PROGEN.ST)

SEK 1.88

(6.21%)

Total Liabilities Summary of Prostatype Genomics AB (publ)

Prostatype Genomics AB (publ)'s latest annual total liabilities in 2023 was 24.54 Million SEK , up 411.5% from previous year.
Prostatype Genomics AB (publ)'s latest quarterly total liabilities in 2024 Q1 was 18.98 Million SEK , down -22.66% from previous quarter.
Prostatype Genomics AB (publ) reported annual total liabilities of 4.79 Million SEK in 2022, up 11.69% from previous year.
Prostatype Genomics AB (publ) reported annual total liabilities of 4.29 Million SEK in 2021, down -20.02% from previous year.
Prostatype Genomics AB (publ) reported quarterly total liabilities of 18.98 Million SEK for 2024 Q2, down 0.0% from previous quarter.
Prostatype Genomics AB (publ) reported quarterly total liabilities of 24.54 Million SEK for 2023 Q4, down 0.0% from previous quarter.

Annual Total Liabilities Chart of Prostatype Genomics AB (publ) (2023 - 2015)

Historical Annual Total Liabilities of Prostatype Genomics AB (publ) (2023 - 2015)

Year	Total Liabilities	Total Liabilities Growth
2023	24.54 Million SEK	411.5%
2022	4.79 Million SEK	11.69%
2021	4.29 Million SEK	-20.02%
2020	5.37 Million SEK	0.0%
2018	9.02 Million SEK	-33.07%
2017	13.48 Million SEK	181.8%
2016	4.78 Million SEK	-12.42%
2015	5.46 Million SEK	0.0%

Year	Total Liabilities	Total Liabilities Growth
2024 Q1	18.98 Million SEK	-22.66%
2024 Q2	18.98 Million SEK	0.0%
2023 Q4	24.54 Million SEK	0.0%
2023 FY	24.54 Million SEK	411.5%
2023 Q3	24.54 Million SEK	321.43%
2023 Q2	5.82 Million SEK	8.23%
2023 Q1	5.38 Million SEK	12.15%
2022 Q4	4.79 Million SEK	-5.85%
2022 Q3	5.09 Million SEK	-8.15%
2022 FY	4.79 Million SEK	11.69%
2022 Q2	5.54 Million SEK	45.65%
2022 Q1	3.81 Million SEK	-11.33%
2021 FY	4.29 Million SEK	-20.02%
2021 Q2	3.96 Million SEK	4.24%
2021 Q1	3.8 Million SEK	-29.22%
2021 Q4	4.29 Million SEK	12.44%
2021 Q3	3.82 Million SEK	-3.58%
2020 Q3	20.39 Million SEK	84.34%
2020 Q2	11.06 Million SEK	0.0%
2020 FY	5.37 Million SEK	0.0%
2020 Q4	5.37 Million SEK	-73.66%
2019 Q3	3.32 Million SEK	0.0%
2018 FY	9.02 Million SEK	-33.07%
2017 FY	13.48 Million SEK	181.8%
2016 FY	4.78 Million SEK	-12.42%
2015 FY	5.46 Million SEK	0.0%

Peer Total Liabilities Comparison of Prostatype Genomics AB (publ)

Name	Total Liabilities	Total Liabilities Difference
AroCell AB (publ)	11.24 Million SEK	-118.282%
Devyser Diagnostics AB (publ)	125 Million SEK	80.362%
Immunovia AB (publ)	31.69 Million SEK	22.537%
SenzaGen AB	29.56 Million SEK	16.978%
Spermosens AB	13.41 Million SEK	-83.016%